Soleno Therapeutics (SLNO) Income from Continuing Operations (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Income from Continuing Operations of 31378000.0 for Q1 2026, up 171.68% year-over-year from 11549470.2 in Q1 2025, and down 27.63% quarter-over-quarter from 43358000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Income from Continuing Operations for 14 consecutive years, with 31378000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 171.68% year-over-year to 31378000.0; the TTM figure through Mar 2026 stood at 185340000.0 (up 49.26% YoY), while the FY2025 annual figure was 53539000.0, up 79.34% from the prior year.
- Income from Continuing Operations retreated to 31378000.0 in Q1 2026 per SLNO's latest filing, from 43358000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 43358000.0 in Q4 2025 and bottomed at 173917000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 48240090.12 across 5 years, with a median of 43773000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 1986.87% — and 2025, when it soared 177.79%.
- Soleno Therapeutics' Income from Continuing Operations stood at 62627000.0 in 2022, then surged by 81.09% to 11843000.0 in 2023, then plunged by 370.61% to 55734000.0 in 2024, then surged by 177.79% to 43358000.0 in 2025, then fell by 27.63% to 31378000.0 in 2026.
- Business Quant data shows SLNO's Income from Continuing Operations at 31378000.0 in Q1 2026, 43358000.0 in Q4 2025, and 86159000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 31.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.38 Mn |
| Dec 31, 2025 | 43.36 Mn |
| Sep 30, 2025 | -86.16 Mn |
| Jun 30, 2025 | -173.92 Mn |
| Mar 31, 2025 | -43.77 Mn |
| Dec 31, 2024 | -55.73 Mn |
| Sep 30, 2024 | -173.76 Mn |
| Jun 30, 2024 | -91.99 Mn |
| Mar 31, 2024 | -100.06 Mn |
| Dec 31, 2023 | -11.84 Mn |
| Sep 30, 2023 | -58.17 Mn |
| Jun 30, 2023 | -8.48 Mn |
| Mar 31, 2023 | -8.48 Mn |
| Dec 31, 2022 | -62.63 Mn |
| Sep 30, 2022 | -6.48 Mn |
| Jun 30, 2022 | -7.13 Mn |
| Mar 31, 2022 | -6.22 Mn |
| Dec 31, 2021 | -3.00 Mn |
| Sep 30, 2021 | -8.34 Mn |
| Jun 30, 2021 | -11.70 Mn |